A Precision Medicine Approach to Prazosin for PTSD and Its Comorbidities: An Update - PTSD: National Center for PTSD
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

PTSD: National Center for PTSD

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
 

A Precision Medicine Approach to Prazosin for PTSD and Its Comorbidities: An Update

 
Share this page

Continuing Education

This section brings together free in-depth Continuing Education resources for the Professional community concerned with trauma.

A Precision Medicine Approach to Prazosin for PTSD and Its Comorbidities: An Update

  • Date Created: 07/ 8/2021
  • Time to Complete: 1 hour
  • Credits: ANCC, APA, ASWB, ACCME, NBCC, Other Orgs
  • Skill Level: Intermediate
  • Course Series: PTSD 101, PTSD Consultation Lecture Series

Start Learning

Credit

VA Only: Go to TMS

Take the Course

Go to TRAIN websiteLink will take you outside the VA website. VA is not responsible for the content of the linked site.

Earn CE/CME Credits

See How to Get Credits.

A Precision Medicine Approach to Prazosin for PTSD and Its Comorbidities: An Update Author(s):

Murray Raskind, MD

Description

Excessive noradrenergic signaling is the most consistently demonstrated neurobiologic abnormality in PTSD. This disturbance also characterizes alcohol use disorder (AUD), a common comorbidity of PTSD.

This course reviews the research for the efficacy of prazosin—a CNS penetrant agonist of noradrenaline signaling at the postsynaptic alpha 1 noradrenergic receptor—in reducing PTSD trauma nightmares, sleep disruption and daytime hyperarousal among Veterans. In addition, the author summarizes the research supporting prazosin efficacy for AUD.

Not all persons with PTSD or with AUD benefit from prazosin. Emerging evidence suggests that the presence of physiologic and clinical signs and symptoms consistent with increased noradrenergic signaling provide a personalized medicine approach to identifying those individuals most likely to benefit from prazosin treatment. The author describes the clinical characteristics that help predict prazosin efficacy in PTSD and AUD.

Goals and Objectives

  • Describe the rationale for prazosin use in PTSD and alcohol use disorder
  • Describe the evidence base for prazosin efficacy in PTSD and the variability in randomized controlled trial participant responses to prazosin
  • Identify clinical characteristics that identify those patients most likely to benefit from prazosin treatment

PTSD Information Voice Mail: (802) 296-6300
Email: ncptsd@va.gov
Also see: VA Mental Health